Grant Zeng, CFA
Research analyst, CFA, biotech, small-cap

Novelos Therapeutics: Unique Platform Technology Targets Cancer Imaging And Therapy

(Editors' Note: This article covers a micro-cap stock. Please be aware of the risks associated with these stocks.)


Novelos Therapeutics, Inc. (NVLT) is a development stage pharmaceutical company focused on the development of compounds for the diagnosis and treatment of cancer.

NVLT is developing three candidates, which are nicknamed as LIGHT, HOT and GLOW2, which are cancer-targeted compounds. All three compounds are selectively taken up and retained in cancer cells, including cancer stem cells, versus normal cells. This offers the potential for a paradigm shift in cancer therapy by providing efficacy versus all three major drivers of mortality in cancer: primary tumors, metastases and stem cell-based relapse.

(click to enlarge)(click to enlarge)

  • 124I-CLR1404
Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details